Mahmood Tahmina, Zaghi Daniel, Menter Alan
Texas A&M Health Science Center College of Medicine , 8447 Texas 47, Bryan, TX 77807 , USA.
Expert Opin Emerg Drugs. 2015 Jun;20(2):209-20. doi: 10.1517/14728214.2015.1010509. Epub 2015 Feb 3.
Psoriasis is a chronic, immune-mediated inflammatory disease that classically presents with well-demarcated, scaly, erythematous plaques on the extensor surfaces of the extremities, scalp, and trunk. Nails and joints are frequently affected as well. Whereas a significant number of patients maintain adequate control with topical therapy, up to 25% of patients will require phototherapy, oral systemic medication, or biologic therapy.
The majority of recent advances in therapeutic options for moderate-to-severe psoriasis have been in biologic therapies whereas development of new oral agents has lagged behind. Currently, oral agents are largely confined to methotrexate, acitretin, cyclosporine and most recently apremilast. This article reviews emerging oral treatments for moderate-to-severe psoriasis.
Despite the recent FDA approval of apremilast, the development of new oral treatments for moderate-to-severe psoriasis has not kept pace with biologic therapies. There continues to be a need for safe and effective long-term oral therapies.
银屑病是一种慢性、免疫介导的炎症性疾病，典型表现为四肢伸侧、头皮和躯干上边界清晰、有鳞屑的红斑斑块。指甲和关节也常受累。虽然相当数量的患者通过局部治疗能维持充分控制，但高达25%的患者将需要光疗、口服全身用药或生物治疗。
中重度银屑病治疗选择的大多数最新进展在于生物治疗，而新型口服药物的研发则滞后。目前，口服药物主要限于甲氨蝶呤、阿维A、环孢素以及最近的阿普斯特。本文综述了中重度银屑病的新兴口服治疗方法。
尽管阿普斯特最近获得了美国食品药品监督管理局（FDA）的批准，但中重度银屑病新型口服治疗方法的研发并未跟上生物治疗的步伐。仍然需要安全有效的长期口服疗法。
